Role of Bone Marrow Transplantation in Lysosomal Storage Disorders

Role of Bone Marrow Transplantation in Lysosomal Storage Disorders

Lysosomal storage disorders (LSDs) are a group of rare, inherited metabolic diseases characterised by the accumulation of undigested macromolecules in lysosomes due to enzyme deficiencies. This accumulation leads to progressive cellular damage, multi-organ dysfunction, and often severe neurological decline. While various treatment options exist, bone marrow transplantation (BMT)more precisely, haematopoietic stem cell transplantation (HSCT)has emerged as a potentially curative therapy for select LSDs, especially those with early onset and severe progression.

This article explores the pathophysiology of LSDs, the rationale behind using BMT, the specific disorders where BMT is applied, treatment outcomes, challenges, and future directions.

Understanding Lysosomal Storage Disorders

Lysosomes are cellular organelles responsible for breaking down various substrates through hydrolytic enzymes. Genetic mutations that cause deficiency or malfunction of these enzymes result in lysosomal storage diseases. Over 50 different LSDs have been identified, each caused by a deficiency of a specific enzyme or protein.

Common LSDs include:

• Hurler syndrome (Mucopolysaccharidosis type I, MPS I-H)

• Metachromatic leukodystrophy (MLD)

• Krabbe disease (Globoid cell leukodystrophy)

• Gaucher disease

• Niemann-Pick disease

• Pompe disease

Many LSDs affect the central nervous system (CNS), leading to progressive neurodegeneration, developmental delays, and early death if untreated.

Pathophysiology and Clinical Manifestations

The deficient lysosomal enzyme causes substrate accumulation within cells, impairing cellular function. The clinical spectrum varies widely:

• Neurological involvement: developmental regression, seizures, spasticity, cognitive decline

• Skeletal abnormalities: dysostosis multiplex, joint stiffness

• Organomegaly: enlargement of liver and spleen

• Cardiac involvement: valve disease or cardiomyopathy in some LSDs

Because many enzymes cannot cross the blood-brain barrier, systemic therapies often fail to halt neurological decline, highlighting the need for treatments that target the CNS.

Rationale for Bone Marrow Transplantation

Haematopoietic stem cell transplantation (HSCT) involves replacing the patients defective haematopoietic system with donor stem cells capable of producing the missing enzyme. Donor-derived cells, especially microglial cells in the CNS, can engraft and provide a source of enzyme that helps break down accumulated substrates.

The advantages of HSCT in LSDs include

• Cross-correction: Donor cells secrete the functional enzyme, which can be taken up by recipient cells via mannose-6-phosphate receptors, restoring lysosomal function.

• CNS benefit: Donor-derived microglia can cross the blood-brain barrier and mitigate neurological damage.

• Long-term enzyme supply: Unlike enzyme replacement therapy (ERT), HSCT provides a potentially lifelong source of enzyme production.

LSDs for Which BMT/HSCT is Used

1. Mucopolysaccharidosis Type I-Hurler Syndrome (MPS I-H)

• Background: MPS I-H is a severe form caused by alpha-L-iduronidase deficiency, leading to glycosaminoglycan (GAG) accumulation.

• Clinical course: progressive neurodegeneration, skeletal deformities, cardiac issues, and early death.

• HSCT Role: Early HSCT (ideally before 2 years old) significantly improves survival and halts neurodegeneration. It can preserve cognitive function and improve somatic symptoms.

• Outcomes: Long-term survivors show improved quality of life, though some skeletal and cardiac abnormalities may persist.

2. Metachromatic Leukodystrophy (MLD)

• Background: Caused by arylsulfatase A deficiency leading to the accumulation of sulfatides that damage myelin.

• Clinical course: progressive demyelination, motor decline, and cognitive impairment.

• HSCT Role: HSCT is more effective when performed in pre-symptomatic or early symptomatic patients, particularly in the juvenile and late-infantile forms.

• Outcomes: HSCT can stabilise or slow neurological decline but is less effective once advanced symptoms develop.

3. Krabbe Disease

• Background: Deficiency of galactocerebrosidase leads to toxic accumulation of psychosine, causing demyelination.

• Clinical course: Thesevere infantile form leads to rapid neurodegeneration and death within the first two years.

• HSCT Role: Early HSCT (within the first few weeks of life) improves survival and neurological outcomes.

• Outcomes: Patients treated early show better motor function and delayed progression, though outcomes remain guarded.

Other LSDs and Experimental Use

HSCT has been attempted in other LSDs such as Gaucher disease and Niemann-Pick disease, but enzyme replacement therapies have largely supplanted transplantation due to lower risk profiles. In some cases, combined approaches using gene therapy and HSCT are under investigation.

Procedure and Conditioning

HSCT for LSDs generally involves

• Donor selection: Matched sibling donors provide the best outcomes, but matched unrelated donors and haploidentical donors are options.

• Conditioning regimen: Chemotherapy to suppress the immune system and allow donor cell engraftment. Regimens are tailored to minimise toxicity.

• Stem cell infusion: via intravenous administration.

• Engraftment and monitoring: Regular evaluation of donor chimerism, enzyme levels, neurological status, and organ function.

Outcomes and Prognostic Factors

• Early transplantation: Age at transplant is the strongest predictor of outcome. Presymptomatic or minimally symptomatic patients benefit most.

• Neurological status: Transplant can halt progression but may not reverse existing damage.

• Donor chimerism: High donor cell engraftment correlates with better enzyme production.

• Complications: Risk of graft-versus-host disease (GVHD), infections, and transplant-related mortality.

Limitations and Challenges

• Transplant risks: GVHD, infections, organ toxicity, and mortality.

• Incomplete correction: Skeletal and cardiac abnormalities may persist.

• Timing: Need for early diagnosis, often requiring newborn screening or family history awareness.

• Availability of donors: Finding suitable donors can delay transplantation.

Future Directions

• Gene therapy: Experimental gene editing and viral vector delivery may allow correction of patient cells without the need for donor stem cells.

• Improved conditioning: Reduced-intensity regimens to minimise toxicity.

• Combination therapies: HSCT combined with enzyme replacement or small molecule therapies.

• Better diagnostics: Newborn screening and earlier diagnosis enable timely intervention.

Conclusion

Bone marrow transplantation remains a cornerstone in the treatment of selected lysosomal storage disorders, especially for early-onset diseases with CNS involvement like Hurler syndrome, MLD, and Krabbe disease. HSCT offers the potential to halt or significantly slow disease progression by restoring deficient enzyme activity through donor-derived cells. Early diagnosis and transplantation before significant neurological damage are critical for optimising outcomes. Despite risks, advances in transplant techniques, donor matching, and supportive care continue to improve survival and quality of life for these patients. Emerging therapies such as gene therapy hold promise for even better future outcomes, potentially reducing the need for transplantation altogether.